CO HB1102

Requires drug manufacturers to report production costs to the Colorado Commission on Affordable Health Care for prescription drugs with wholesale acquisition costs of $50,000 or more annually or per course of treatment by August 1, 2016.

Manufacturers must itemize and report research and development costs, clinical trial and regulatory costs, materials and manufacturing costs, government subsidies or grants, patent and licensing costs, and marketing and advertising expenses.

Manufacturers must also report cumulative annual price increases, total company profits attributable to the drug, and financial assistance provided through patient prescription assistance programs.

The Colorado Commission on Affordable Health Care must develop a reporting form by June 1, 2016, and submit an analysis report to specified legislative committees by December 1, 2016, including recommendations for legislative or policy changes based on manufacturer data.

The reporting requirement expires July 1, 2017.